Cancer tumor profiling market seen reaching $28.27 billion by 2030

The Business Research Company projects the cancer tumor profiling market will rise from $14.97 billion in 2025 to $28.27 billion by 2030, driven by precision oncology, sequencing tools and predictive diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Cancer tumor profiling is becoming a core tool in oncology because it helps identify tumor characteristics that can guide treatment decisions. - The market’s growth reflects rising demand for precision oncology, personalized treatment planning and predictive diagnostics. - Expanding cancer incidence worldwide continues to increase the need for molecular testing and profiling services.

What happened: - The Business Research Company released a market outlook projecting the cancer tumor profiling market will reach $28.27 billion by 2030. - The report estimates the market at $14.97 billion in 2025 and $17.1 billion in 2026. - The forecast implies a 13.4% compound annual growth rate from 2026 through 2030. - The release says North America held the largest market share in 2025. - The release says Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Cancer tumor profiling tests tumor tissue for genes, mutations, proteins and other biomarkers. - The testing is used to help shape treatment strategies and assess the likelihood of recurrence or spread. - Growth through 2026 was tied to higher use of tumor biopsy testing, more oncology research, early adoption of molecular stratification, hospital-based profiling services and broader lab infrastructure. - Growth beyond 2026 is linked to rising use of precision oncology tools, personalized cancer treatments, translational research investment, sequencing technologies and predictive oncology diagnostics. - Key trends highlighted in the report include multi-omics tumor profiling, targeted sequencing panels, AI-driven biomarker analysis, personalized treatment planning and prognostic profiling. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market thesis is built on a shift from broad cancer testing toward more individualized care. - The report also suggests tumor profiling is moving from a specialist tool to a more routine part of oncology workflows. - Rising cancer incidence is reinforcing demand even as some individual cancer types may fluctuate by region or over time. - The emphasis on AI, multi-omics and targeted panels points to a market that is becoming more data-intensive and more dependent on advanced lab capabilities.

What's next: - The market is projected to keep expanding through 2030 as precision oncology adoption widens. - The report expects deeper use of sequencing-based diagnostics and AI-enabled biomarker interpretation. - North America is likely to remain a major market, while Asia-Pacific should capture the fastest growth. - The company is offering the full report and a free sample for readers seeking more detail: More information and download a free sample.

The bottom line: - Cancer tumor profiling is moving into a high-growth phase as oncology increasingly depends on molecular data to guide treatment.